Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

A Phase 1 Study of Daratumumab-SC for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation

The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

Study Overview

• Status: Completed
• Conditions: Heart Transplant Failure and Rejection; Allosensitization
• Intervention / Treatment: Drug: Daratumumab-SC

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Stacy Kobayashi; Phone Number: 650-723-2805; Email: stacyk@stanford.edu

Study Locations

• United States
  • California
    • Stanford, California, United States, 94304
      • Stanford Health Care

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant is on an active list for a heart transplant.
• Participant has a high level of allosensitization, defined as a calculated PRA (panel of reactive antibodies) of 50%, based on their antibody status at the time of entry into the study.
• Ability to understand and willingness to sign an informed consent form prior to any study-related procedures.
• Women of childbearing potential must have a negative pregnancy test at screening.
• Both male and female patients must use effective methods of birth control, must not donate eggs or sperm during the course of the study and for 3 months after stopping daratumumab-SC.
• Adequate bone marrow function.
• Adequate renal function (estimated GFR greater than or equal to 15 mL/min by the Cockcroft-Gault formula).

Exclusion Criteria:

• History of allergy or intolerance to daratumumab or Daratumumab-SC.
• Prior diagnosis of myeloma or light chain amyloidosis.
• Active infection.
• Women who are pregnant or breastfeeding.

• Ongoing desensitization treatment with another agent. Subjects are excluded if they have received:

  • a. IVIG within 30 days of enrollment.
  • b. Proteasome inhibitor within 60 days of enrollment.
  • c. Rituximab within 180 days of enrollment.
• Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study.
• Contraindication to herpes zoster prophylaxis.
• Known to be seropositive for human immunodeficiency virus (HIV).
• Known to be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
• Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).
• Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.
• Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
• Known history of human immunodeficiency virus (HIV).
• History of blood product transfusion within 60 days of enrollment, or anticipated need for blood product transfusion during the course of the study.
• Moderate-severe liver dysfunction.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Daratumumab-SC Injection; Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.; Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study.	Drug: Daratumumab-SC; >Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels before and after treatment.	Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 12.	Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent MFI change for each individual preformed HLA antibody at Week 6.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 6 or the time of heart transplantation (whichever is earlier).	Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier).
Percent MFI change for each individual preformed HLA antibody at Week 12.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 12 or the time of heart transplantation (whichever is earlier).	Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier).
Percent MFI change for each individual preformed HLA antibody at Week 15.	Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 15 or the time of heart transplantation (whichever is earlier).	Baseline and Week 15 (or the last measurement prior to heart transplantation, whichever is earlier).
Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels at baseline and Week 6.	Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 6.	Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier).

Collaborators and Investigators

• Sponsor: Ronald Witteles
• Investigators: Principal Investigator: Ronald M Witteles, MD, Stanford University

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2021
• Primary Completion (Actual): January 26, 2024
• Study Completion (Actual): January 26, 2024

Study Registration Dates

• First Submitted: October 26, 2020
• First Submitted That Met QC Criteria: October 26, 2020
• First Posted (Actual): October 30, 2020

Study Record Updates

• Last Update Posted (Actual): March 25, 2024
• Last Update Submitted That Met QC Criteria: March 21, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Immunotherapy, anti-CD38 antibody
• Additional Relevant MeSH Terms: Antineoplastic Agents; Daratumumab
• Other Study ID Numbers: 53476

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No